Voronoi's confirmed schedule has three threads. First, VRN11 is running global Phase 1b/2 trials in Australia, Hong Kong, Singapore, Malaysia and Thailand, and the Thai trial application was approved and disclosed on September 14, 2026.
Second, VRN11's Canadian trial application was voluntarily withdrawn on September 9, 2026 to reflect the regulator's review comments, and the company said it plans to resubmit after updating the data.
Third, a corrective disclosure on October 20, 2026 added France and Spain as European trial countries for the VRN11 Phase 1/2 study.
On first-line treatment, a late-2025 press report set a target of starting a first-line trial in treatment-naive patients in the first half of 2026; whether it has started and what interim results show should be checked against later disclosures and conference presentations. VRN10 is planned to enter Phase 1b in 2027.
For VRN07, Oric has completed end-of-Phase 1 discussions with the US FDA and plans to start the global Phase 3 Redwood-1 in the first half of 2027. The development milestones Voronoi could receive total up to USD 158 million and are paid as stages are reached.
On funding, the KRW 52.7 billion convertible bond has a 0% coupon, a 2% yield to maturity, and a November 23, 2031 maturity, with a conversion price of KRW 111,510 per share. The floor for conversion price adjustments if the share price falls is set at 70% of the original conversion price.
The 2026 annual report, the next periodic filing, will show whether the annual loss and cash burn change from 2025.